Section Arrow
Quote
INSM.NASDAQ
- Insmed Incorporated
Quotes are at least 15-min delayed:2026/02/23 12:26 EST
Regular Hours
Last
 160.475
-4.435 (-2.69%)
Day High 
167 
Prev. Close
164.91 
1-M High
167.37 
Volume 
665.17K 
Bid
160.28
Ask
160.67
Day Low
159.75 
Open
163.6 
1-M Low
142.99 
Market Cap 
35.17B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 151.88 
20-SMA 154.13 
50-SMA 167.48 
52-W High 212.75 
52-W Low 60.4 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.19/0.18
Enterprise Value
36.31B
Balance Sheet
Book Value Per Share
4.43
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
11.70M
Operating Revenue Per Share
1.32
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOSSGossamer Bio0.3512-1.7788-83.51%-- 
IBRXImmunityBio10.075+1.375+15.80%-- 
IKTInhibikase Therapeutics1.995+0.235+13.35%3.74PE
VNDAVanda Pharmaceuticals8.0665+2.3065+40.04%-- 
ACLXArcellx113.84+49.73+77.57%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from theUnited States from the sale of its commercial products.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.